Market Study of Global Graft Versus Host Disease Industry 2019 by smit510 · January 15 Broncos Royce Freeman Jersey , 2019
ResearchMoz presents professional and in-depth study of “Competitor Landscape: Graft Versus Host Disease (GVHD)”.
Summary
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the graft versus host disease (GVHD) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development Broncos Courtland Sutton Jersey , or higher –
Get PDF for more Professional and Technical insights @ ;repid=1978211
– Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape – Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies – Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019 – Approved Product Landscape: An overview of pipeline candidates Broncos Bradley Chubb Jersey , containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Key Highlights
– Anticipated approval of ATIR101 is delayed both in the EU and US – with the postponed primary completion date in the ongoing Phase III trial delaying the expected US approval by 9 months – If approved, Ruxolitinib for use in combination with corticosteroids for the treatment of steroid-refractory aGVHD would make it the second drug to receive US approval for the treatment of GVHD after JanssenAbbVies IBR – Incyte has not only delayed the initiation of Itacitinib’s GRAVITAS-309 trial, but significantly extended its duration (from ~2.5 years to ~4.5 years).
View Complete TOC with tables & Figures @
Scope
– The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases Broncos Phillip Lindsay Jersey , earnings calls) and clinical trial databases ( ) – Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix – Forecasts are presented in pipeline forecast figures & detailed tables – Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy
– Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher – Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market – Reviews ongoing lifecycle management strategies for existing players in the market – A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents Introduction to Sociable Pharmas GVHD Competitor Landscape Executive Summary Overall GVHD Landscape Key Events & Landscape Updates Landscape Updates Order of Entry Direction of Travel & Market Entry Strategies Pipeline & Approved Product Landscape
Mamis mit Herz
Thema drucken
23.09.2019 08:02
Antworten
